filmov
tv
Empagliflozin: Protecting Kidneys Even After Stopping?
Показать описание
The EMPA-KIDNEY trial studied over 6,600 patients with chronic kidney disease to see if Empagliflozin continues to protect the kidneys and heart after stopping the medication. The results? Lower risk of kidney disease progression and cardiovascular death, even 12 months after discontinuation!Could this change CKD management? Watch to find out!📌 Follow @Updates_in_Medicine for the latest clinical research.#Empagliflozin #CKD #Nephrology #Cardiology #SGLT2 #MedicalResearch #ClinicalTrials #KidneyHealth #HeartHealth
0:00:54
0:01:52
0:00:58
0:09:06
0:14:52
0:59:24
0:02:41
0:00:42
0:12:30
0:03:41
0:10:55
0:06:57
0:00:08
0:00:50
0:59:34
0:03:21
0:00:50
0:03:28
0:57:22
0:00:54
0:53:13
0:00:08
0:02:03
0:39:11